Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of M118103 in prurigo nodularis
jRCT2031210028Phase 2Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tofacitinib in prurigo nodularis (PN) (3 arms), sponsored by Maruho Co., Ltd. Primary endpoint: Responder rate based on nodule thickness reduction. Started Jun 2021; status: completed.
02
Drugs
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on jRCT2031210028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210028.